RU2020133171A3 - - Google Patents

Download PDF

Info

Publication number
RU2020133171A3
RU2020133171A3 RU2020133171A RU2020133171A RU2020133171A3 RU 2020133171 A3 RU2020133171 A3 RU 2020133171A3 RU 2020133171 A RU2020133171 A RU 2020133171A RU 2020133171 A RU2020133171 A RU 2020133171A RU 2020133171 A3 RU2020133171 A3 RU 2020133171A3
Authority
RU
Russia
Application number
RU2020133171A
Other languages
Russian (ru)
Other versions
RU2020133171A (ru
Filing date
Publication date
Priority claimed from US15/916,689 external-priority patent/US10869887B2/en
Application filed filed Critical
Publication of RU2020133171A publication Critical patent/RU2020133171A/ru
Publication of RU2020133171A3 publication Critical patent/RU2020133171A3/ru

Links

RU2020133171A 2015-09-11 2019-03-08 Биологически значимые ортогональные пары цитокинов/рецепторов RU2020133171A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562217364P 2015-09-11 2015-09-11
US201662375089P 2016-08-15 2016-08-15
US15/916,689 2018-03-09
US15/916,689 US10869887B2 (en) 2015-09-11 2018-03-09 Biologically relevant orthogonal cytokine/receptor pairs
PCT/US2019/021451 WO2019173773A1 (en) 2015-09-11 2019-03-08 Biologically relevant orthogonal cytokine/receptor pairs

Publications (2)

Publication Number Publication Date
RU2020133171A RU2020133171A (ru) 2022-04-12
RU2020133171A3 true RU2020133171A3 (cg-RX-API-DMAC7.html) 2022-09-09

Family

ID=58240003

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020133171A RU2020133171A (ru) 2015-09-11 2019-03-08 Биологически значимые ортогональные пары цитокинов/рецепторов

Country Status (17)

Country Link
US (7) US10869887B2 (cg-RX-API-DMAC7.html)
EP (2) EP3347056A4 (cg-RX-API-DMAC7.html)
JP (5) JP7299021B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250004916A (cg-RX-API-DMAC7.html)
CN (4) CN108430518A (cg-RX-API-DMAC7.html)
AR (1) AR114687A1 (cg-RX-API-DMAC7.html)
AU (4) AU2016318621A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020018293A2 (cg-RX-API-DMAC7.html)
CA (2) CA2998393A1 (cg-RX-API-DMAC7.html)
HK (1) HK1258138A1 (cg-RX-API-DMAC7.html)
IL (2) IL277118B2 (cg-RX-API-DMAC7.html)
MX (1) MX428362B (cg-RX-API-DMAC7.html)
PH (1) PH12020551417A1 (cg-RX-API-DMAC7.html)
RU (1) RU2020133171A (cg-RX-API-DMAC7.html)
SG (1) SG11202008780SA (cg-RX-API-DMAC7.html)
WO (2) WO2017044464A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006168B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7299021B2 (ja) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020131547A1 (en) * 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
MX2021011258A (es) * 2019-03-18 2021-12-10 Biontech Cell & Gene Therapies Gmbh Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activacion especifica de celulas efectoras inmunitarias.
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN114555634B (zh) * 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
CA3151471A1 (en) * 2019-10-08 2021-04-15 Gesa VOLKERS Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
US11648296B2 (en) * 2019-12-13 2023-05-16 Synthekine, Inc. IL-2 orthologs and methods of use
IL293978A (en) * 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115315273A (zh) * 2020-01-14 2022-11-08 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
KR20220131529A (ko) * 2020-01-14 2022-09-28 신테카인, 인크. 변경된 icd stat 신호전달을 갖는 cd122
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
BR112022017656A2 (pt) * 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
JP2023520572A (ja) * 2020-04-06 2023-05-17 シンセカイン インコーポレイテッド オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞
WO2021207290A1 (en) * 2020-04-06 2021-10-14 Synthekine, Inc. Engineered immune cells
KR20230060514A (ko) * 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
CN116529257A (zh) * 2020-10-26 2023-08-01 尼普图恩生物科学有限公司 正交il-21受体/细胞因子系统
WO2022093683A1 (en) * 2020-10-26 2022-05-05 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4305054A4 (en) * 2021-03-09 2025-03-19 The Trustees of The University of Pennsylvania SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL ADMINISTRATION OF ORTHOGONAL IL-2
US20240182584A1 (en) * 2021-04-02 2024-06-06 The Board Of Trustees Of The Leland Stanford Junior University Bispecific Molecules and Related Compositions and Methods
WO2022213208A1 (en) * 2021-04-07 2022-10-13 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
EP4370139A4 (en) * 2021-07-14 2025-10-15 Synthekine Inc METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
EP4402161A1 (en) 2021-09-17 2024-07-24 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
PE20242341A1 (es) * 2022-04-04 2024-12-12 Gammadelta Therapeutics Ltd Blindaje genetico novedoso
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors
CN121013867A (zh) * 2023-06-07 2025-11-25 Fbd生物制品有限公司 工程化的il-7变体及其使用方法
WO2025245495A1 (en) * 2024-05-24 2025-11-27 Cz Biohub Sf, Llc Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
US20060199250A1 (en) * 2005-03-04 2006-09-07 Huimin Zhao Method for generating a mutant protein which efficiently binds a target molecule
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
LT2884999T (lt) * 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
US9434935B2 (en) * 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
JP7299021B2 (ja) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
CN107746831B (zh) 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Similar Documents

Publication Publication Date Title
BR102023005164A2 (cg-RX-API-DMAC7.html)
BR102022025291A2 (cg-RX-API-DMAC7.html)
BR102022017795A2 (cg-RX-API-DMAC7.html)
BR112025024041B1 (pt) Elemento de despejamento para uma embalagem compósita e embalagem compósita com um elemento de despejamento
BR112025020304B1 (pt) Liga de solda, esfera de solda, pré-forma de solda, junta de solda e circuito
BR112025008516B1 (pt) Método tudo em um de recuperação de níquel para recuperar níquel a partir de matérias-primas contendo níquel
BR112025016688B1 (pt) Compostos e composições farmacêuticas
BR112025011041B1 (pt) Dispositivo para inspeção de um elemento roscado e método de inspeção correspondente
BR112024022558B1 (pt) Polipeptídeo, polinucleotídeo, ácido nucleico, vetor, célula hospedeira, método para produzir o polipeptídeo, composição, e, método in vitro para aumentar adesão celular
BR112025005915B1 (pt) Gerador, dispositivo e método de ablação de campo pulsado
BR102023016405B1 (pt) Estrutura de viga de pá, pá de energia eólica e equipamento de energia eólica
BR112024026850B1 (pt) Triturador de mandíbula e método de serviço ou de manutenção de um triturador de mandíbula
BR112024025233B1 (pt) Método para alterar o estado de elevação vertical para um veículo transportador, controle e veículo
BR102023009702B1 (pt) Dispositivo para alisamento e aplicação de substância de tratamento
BR112024019620B1 (pt) Derivados de 2-[(2-oxo-4-fenil-2h-cromen-7-il)óxi]propanamido, composições farmacêuticas e usos
BR112024027500B1 (pt) Polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir o polipeptídeo, composição, uso do polipeptídeo, e, método para promover a proliferação de uma célula in vitro
BR102023002997B1 (pt) Um aparelho para detecção de vazamento de um gás e um método e um sistema do mesmo
BR112024018530B1 (pt) Método para determinar nível de escória do alto-forno, método para operar alto-forno e unidade de controle
BR112024027130B1 (pt) Sistema e método para um conjunto de cuff (balão) de tubo endotraqueal
BR112025001284B1 (pt) Cabo, sistema de sensor e método de montagem de um alojamento de sensor
BR102022024748B1 (pt) Equipamento extrator de esporos da superfície de grãos de cereal para aplicação em laboratório e seu processo operacional
BR102022023712B1 (pt) Sistema de montagem de estrutura flexível para estufas agrícolas, com sistema molejante de movimentação em relação à ação dos ventos
BR122025008973A2 (pt) Sistema, método para decodificar um vídeo e mídia legível por computador
BR122025008972A2 (pt) Sistema, método para decodificar um vídeo e mídia legível por computador
BR122025008970A2 (pt) Método para decodificar um vídeo, sistema e mídia legível por computador